OKYO Pharma Files Annual Report, Outlines Cash Position and Plans for Phase 3 Trial
OKYO Pharma (NASDAQ:OKYO) filed its annual report with the SEC and highlighted a strong cash position of $20.6 million as it prepares to launch its global Phase 3 trial for urcosimod in neuropathic corneal pain later this year.